Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Evaluate the Immunogenicity and Safety of Rabies Vaccine Given in a Post-exposure Prophylaxis Regimen to Healthy Children and Adults Aged 10-60 Years.
Authors not listed
Novartis Vaccines · 2006
Abstract
Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2006). Evaluate the Immunogenicity and Safety of Rabies Vaccine Given in a Post-exposure Prophylaxis Regimen to Healthy Children and Adults Aged 10-60 Years. <em>Novartis Vaccines</em>. https://clinicaltrials.gov/study/NCT00345319
Vancouver
Anonymous. Evaluate the Immunogenicity and Safety of Rabies Vaccine Given in a Post-exposure Prophylaxis Regimen to Healthy Children and Adults Aged 10-60 Years. Novartis Vaccines. 2006.
BibTeX
@misc{anon2006Evalua,
title = {Evaluate the Immunogenicity and Safety of Rabies Vaccine Given in a Post-exposure Prophylaxis Regimen to Healthy Children and Adults Aged 10-60 Years.},
author = {Anonymous},
journal = {Novartis Vaccines},
year = {2006},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Sinovac Biotech Co., Ltd 2021
Open access · US-GOV
A Randomized, Double-blind and Active-controlled Phase Ⅰ/Ⅲ Clinical Trial to Evaluate Immunogenicity and Safety of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried, Administered With Different Immunization Schedules in Healthy Individuals Aged 10-60 Years
Guangzhou Patronus Biotech Co., Ltd. 2025
Open access · US-GOV
A Phase Ⅱ, Randomized, Observer-blinded, Parallel-Controlled Clinical Trial to Assess the Immunogenicity and Safety of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older
Yikang Biotech (Suzhou) Co., Ltd. 2026
Open access · US-GOV
A Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Guangzhou Patronus Biotech Co., Ltd. 2024
Open access · US-GOV
A Phase I, Randomized, Observer-Blinded, Parallel-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), LYB005, in Healthy Adults Aged 18 Years and Older
Beijing Minhai Biotechnology Co., Ltd 2020
Open access · US-GOV
Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial
Beijing Minhai Biotechnology Co., Ltd 2020
Open access · US-GOV